Aminocandin
Also known as: Aminocandin, HMR-3270, IP960, LY303366, SCY-125
Source Aminocandin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Aminocandin is a semisynthetic echinocandin derivative investigated for treatment of invasive candidiasis and other serious fungal infections. It is administered intravenously and acts by blocking β‑1,3‑glucan synthesis in fungal cell walls.
Mechanism of Action
Inhibits fungal β‑1,3‑D‑glucan synthase, weakening the cell wall and causing osmotic lysis.
Routes of Administration
Goals & Uses
- Treatment of invasive aspergillosisAntifungalLow
- Treatment of invasive candidiasisAntifungalModerate
- Invasive aspergillosisAntifungalLow
- Treatment of Pneumocystis pneumoniaAntifungalLow
- Invasive candidiasisAntifungalModerate
Contraindications
- Hypersensitivity to echinocandinsAllergyHigh
- Hypersensitivity to aminocandin or echinocandinsAllergyHigh
- Known hypersensitivity to echinocandinsAllergyHigh
Adverse Effects
- Elevated hepatic transaminasesLiverUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularRareLow blood pressure
- Infusion‑related reactionsGeneralCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityCommon
Drug Interactions
- Cytochrome P450 substratesLow
- CyclosporineModerate
- TacrolimusLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseRelative
Regulatory Status
- European UnionInvestigationalUnder EMA review; not marketed.
- United StatesInvestigationalPhase II trials completed; not FDA‑approved.
- United KingdomUnknownNo MHRA approval; status post-Brexit unclear but presumed unapproved
Never received regulatory approval in any major jurisdiction. Phase II clinical trials were conducted but development was discontinued. Not approved by FDA, EMA, or MHRA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Aminocandin?
Aminocandin is a semisynthetic echinocandin derivative investigated for treatment of invasive candidiasis and other serious fungal infections. It is administered intravenously and acts by blocking β‑1,3‑glucan synthesis in fungal cell walls.
What is Aminocandin used for?
Aminocandin is educationally associated with: Treatment of invasive aspergillosis, Treatment of invasive candidiasis, Invasive aspergillosis, Treatment of Pneumocystis pneumonia, Invasive candidiasis. Educational only — not medical advice.
How is Aminocandin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Aminocandin?
Reported adverse effects include: Elevated hepatic transaminases, Headache, Hypotension, Infusion‑related reactions, Nausea, Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Aminocandin?
Recorded contraindications: Hypersensitivity to echinocandins, Hypersensitivity to aminocandin or echinocandins, Known hypersensitivity to echinocandins. Consult a qualified clinician before use.